U.S. FDA Seizes Chinese Heparin From Medical Devices Firm
This article was originally published in PharmAsia News
U.S. FDA ordered 11 lots of contaminated heparin removed from Celsus Laboratories, which obtained the drug product from China to include in medical devices. The agency ordered the seizures on grounds the products contained over-sulfated chondroitin sulfate. FDA advised companies that may have obtained heparin from Cincinnati-based Celsus to determine if the drug they received came from one of the 11 batches. The agency said it has contacted other countries to warn them of the newly found contaminated heparin produced in China. (Click here for more - a subscription may be required
You may also be interested in...
Avadim Health argues National Advertising Division expects substantiation for its homeopathic topical claims at the same level FDA requires for NDAs. NAD also said although FTC’s competent, reliable scientific evidence standard is “flexible” to some degree, pain claims are held to a more rigid standard.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
The FDA has asked the company for more information to support its PoNS therapy for multiple sclerosis patients with gait deficit, including an additional analysis of clinical data and labeling modifications.